Taro Pharmaceutical Industries Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Uday Baldota

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	6.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	8.7yrs
Promedio de permanencia en la Junta Directiva	7.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Uday Baldota (53 yo)

6.8yrs

Permanencia

Mr. Uday V. Baldota has been Director at Association for Accessible Medicines. He has been the Chief Executive Officer of Taro Pharmaceutical Industries Ltd. since August 28, 2017 and served as its Co-Chie...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Uday Baldota	CEO & Director	6.8yrs	sin datos	sin datos
William Coote	VP, CFO & Chief Accounting Officer	2.4yrs	sin datos	sin datos
Itamar Karsenti	VP & Head of Operations	9.4yrs	sin datos	sin datos
Avi Avramoff	VP and Head of R&D	12.6yrs	sin datos	sin datos
Itzik Baruch	Vice President of Technical Services	14.3yrs	sin datos	sin datos
Roman Kaplan	Vice President of Scientific and Technical Compliance Manager	no data	sin datos	sin datos
Erik Zwicker	VP, General Counsel & Secretary	4.1yrs	sin datos	sin datos
Ara Aprahamian	Vice President of Sales & Marketing	11.2yrs	US$616.14k	sin datos
Michele Visosky	VP & Head of Human Resource	no data	sin datos	sin datos
Jayesh Shah	Head of Procurement	12.4yrs	sin datos	sin datos
Richard Glaze	VP & Head of Information Technology	7.9yrs	sin datos	sin datos
Ori Gutwerg	VP & Head of U.S. Generics Rx	5.1yrs	sin datos	sin datos

8.7yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TAL es experimentado (8.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Uday Baldota	CEO & Director	7.4yrs	sin datos	sin datos
Dilip Shanghvi	Chairman of the Board	10.8yrs	US$1.00m	sin datos
Robert Stein	Independent Director	4.3yrs	sin datos	sin datos
Sudhir Valia	Director	13.7yrs	US$500.00k	sin datos
James Kedrowski	Director	13yrs	sin datos	sin datos
Linda Shushan	Independent Director	7.4yrs	sin datos	sin datos
Abhay Gandhi	Vice Chairman	7.4yrs	sin datos	sin datos
Oded Sarig	Independent Director	less than a year	sin datos	sin datos

7.4yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de TAL se considera experimentada (7.3 años de antigüedad promedio).

Taro Pharmaceutical Industries Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 28, 2023

Taro Pharmaceutical Industries Ltd. Appoints Mr. Oded H. Sarig, Ph. D, to Serve as Director

Taro Pharmaceutical Industries Ltd. Announces Resignation of Dov Pekelman from the Board of Directors

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 29, 2022

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Taro Pharmaceutical Industries Ltd. to Report Fiscal Year 2024 Results on May 20, 2024

Taro Pharmaceutical Industries Ltd. to Report Q3, 2024 Results on Jan 25, 2024

Taro Pharmaceutical Industries to Delist from NYSE

Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 28, 2023

Taro Pharmaceutical Industries Ltd. to Report Q2, 2024 Results on Oct 26, 2023

Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Taro Pharmaceutical Industries Ltd. Appoints Mr. Oded H. Sarig, Ph. D, to Serve as Director

Taro Pharmaceutical Industries Ltd. Announces Resignation of Dov Pekelman from the Board of Directors

Taro Pharmaceutical Industries to be Delisted from NYSE

Full year 2023 earnings released: EPS: US$0.68 (vs US$1.55 in FY 2022)

Taro Pharmaceutical Industries Ltd. to Report Fiscal Year 2023 Results on May 23, 2023

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorates as stock falls 16%

Third quarter 2023 earnings released: EPS: US$0.19 (vs US$0.70 in 3Q 2022)

Taro Pharmaceutical Industries Ltd. to Report Q3, 2023 Results on Jan 24, 2023

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 29, 2022

Less than half of directors are independent

Second quarter 2023 earnings released: US$0.075 loss per share (vs US$0.62 profit in 2Q 2022)

Taro Pharmaceutical Industries Ltd. to Report Q2, 2023 Results on Oct 27, 2022

Taro Pharmaceutical Industries Ltd. to Report Q1, 2023 Results on Jul 27, 2022

Full year 2022 earnings released: EPS: US$1.55 (vs US$10.12 loss in FY 2021)

Full year 2022 earnings released: EPS: US$1.55 (vs US$10.12 loss in FY 2021)

Taro Pharmaceutical Industries Ltd. to Report Fiscal Year 2022 Results on May 26, 2022

Less than half of directors are independent

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) completed the acquisition of Alchemee LLC from Galderma Holding SA.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) entered into a definitive agreement to acquire Alchemee LLC from Galderma Holding SA.

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Taro Pharmaceutical Industries Ltd. Announces Impairment for the Third Quarter Ended December 31, 2021

Second quarter 2022 earnings released: EPS US$0.62 (vs US$1.18 in 2Q 2021)

VP, CFO & Chief Accounting Officer Daphne Huang has left the company

First quarter 2022 earnings released: US$0.50 loss per share (vs US$11.37 loss in 1Q 2021)

Full year 2021 earnings released: US$10.12 loss per share (vs US$6.35 profit in FY 2020)

Full year 2021 earnings released: US$10.12 loss per share (vs US$6.35 profit in FY 2020)

New 90-day high: €65.50

Third quarter 2021 earnings released: EPS US$0.86 (vs US$1.76 in 3Q 2020)

Revenue misses expectations

Taro Pharmaceutical Industries Ltd. to Report Q3, 2021 Results on Jan 27, 2021

New 90-day high: €60.00

New 90-day high: €54.50

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 14, 2020

Second quarter 2021 earnings released: EPS US$1.18

Revenue beats expectations

New 90-day low: €46.00

Taro Launches Specialty Generic Deferiprone Tablets, 500Mg in the U.S

New 90-day low - €48.60

New 90-day low - €51.50

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) completed the acquisition of Aquinox Pharmaceuticals Inc. (Canada), Inc. from Neoleukin Therapeutics, Inc.

New 90-day low - €56.00

Taro Pharmaceutical Industries Ltd. to Report Q1, 2021 Results on Jul 29, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad